<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01013558</url>
  </required_header>
  <id_info>
    <org_study_id>P04.014</org_study_id>
    <nct_id>NCT01013558</nct_id>
  </id_info>
  <brief_title>New Options for Preoperative Anesthesia in Intrauterine Needling</brief_title>
  <acronym>NO PAIN</acronym>
  <official_title>NO PAIN: New Options for Preoperative Anesthesia in Intrauterine Needling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leuven University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The concept of fetal pain is becoming increasingly relevant due to growing possibilities for
      invasive intrauterine treatment. There is much debate as to whether the fetus is mature
      enough to be able to perceive pain at all. Recent studies have suggested that the fetus is at
      least capable of exhibiting a stress response to intrauterine needling. Intrauterine
      transfusions are most commonly performed by inserting a needle either in the umbilical cord
      root at the placental surface, or in the intrahepatic portion of the umbilical vein of the
      fetus. Recently, intrauterine needling in the intrahepatic vein has been shown to result in
      alterations in fetal stress hormones, which has been interpreted as a reaction to pain. These
      changes were not observed in intrauterine needling in the umbilical cord root, or after
      administration of analgesics to the fetus. The investigators tested the hypothesis that
      remifentanil provides fetal analgesia, assessed by a reduced fetal stress response. The
      investigators performed a randomised controlled trial comparing fetal stress response between
      patients undergoing intrauterine transfusions for alloimmune fetal anemia receiving
      remifentanil, or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evidence of fetal stress response by changes in fetal stress hormones beta-endorphin, noradrenalin and cortisol</measure>
    <time_frame>15-60 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>influence of analgesics (remifentanil) on the fetal stress response</measure>
    <time_frame>15-60 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Stress</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>0.15 microgram/kg/min continuous infusion.</description>
    <arm_group_label>remifentanil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>continuous infusion</description>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  singleton pregnancy

          -  clinically indicated intrauterine transfusion

          -  red cell alloimmunisation

        Exclusion Criteria:

          -  severe adipositas

          -  suspicion of structural anomalies

          -  fetal hydrops

          -  contraindication for remifentanil
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank P.H.A. Vandenbussche, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2009</study_first_submitted>
  <study_first_submitted_qc>November 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2009</study_first_posted>
  <last_update_submitted>December 7, 2009</last_update_submitted>
  <last_update_submitted_qc>December 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>F.P.H.A. Vandenbussche, MD PhD</name_title>
    <organization>Leiden University Medical Center</organization>
  </responsible_party>
  <keyword>fetal pain</keyword>
  <keyword>intrauterine</keyword>
  <keyword>needling</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

